{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:53:10Z","timestamp":1792666390934,"version":"4.5.0"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi251054-4\"><jats:title>Importance<\/jats:title><jats:p>Although messenger RNA (mRNA) COVID-19 vaccines are widely recommended during pregnancy, data on their fetal safety during the teratogenic window remain limited.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi251054-5\"><jats:title>Objective<\/jats:title><jats:p>To evaluate the association between first-trimester exposure to mRNA COVID-19 vaccines and the risk of major congenital malformations (MCMs), across 75 individual MCMs grouped by 13 organ systems.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi251054-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This nationwide, population-based cohort study was conducted using the comprehensive Mother-Child EPI-MERES Register, including all live-born infants in France from pregnancies starting April 1, 2021, to January 31, 2022. Follow-up data were available up to December 2024.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi251054-7\"><jats:title>Exposure<\/jats:title><jats:p>Exposure was defined as receiving at least 1 dose of mRNA-based COVID-19 vaccine during the first trimester of pregnancy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi251054-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>MCMs were identified following European Surveillance of Congenital Anomalies guidelines. The main analyses compared exposed and nonexposed infants, and sensitivity analyses used alternative comparison groups based on maternal vaccination status and timing. Confounders were adjusted for using a propensity score\u2013based standardized mortality ratio weighting method. Weighted odds ratios (ORs) were estimated using logistic regression.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi251054-9\"><jats:title>Results<\/jats:title><jats:p>Among 527\u202f564 eligible live-born infants, 130\u202f338 (24.7%) were exposed to at least 1 vaccine dose during the first trimester. Mothers of exposed infants were slightly older than mothers of unexposed infants (mean [SD] age, 30.4 [5.3] years vs 30.1 [5.1] years), were less socially deprived, and presented slightly more often with a comorbidity. The prevalence of MCMs was 176.6 per 10\u202f000 (2302 infants) among exposed infants and 179.4 per 10\u202f000 (7128 infants) among nonexposed infants. No increased risk of MCMs was observed overall (weighted OR, 0.98 [95% CI, 0.93-1.04]), by organ system (weighted ORs ranging from 0.84 [95% CI, 0.68-1.04] for digestive system MCMs to 1.20 [95% CI, 0.75-1.91] for abdominal wall defects), or for any of the 75 individual MCMs. Sensitivity and stratified analyses confirmed these findings.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi251054-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this cohort study of pregnancies exposed to mRNA COVID-19 vaccines in the first trimester, exposure was not associated with an increased risk of any MCMs, overall, by organ group, or by individual MCM, supporting the safety of mRNA COVID-19 vaccines in early pregnancy.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.38039","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:01:54Z","timestamp":1760540514000},"page":"e2538039","source":"Crossref","is-referenced-by-count":13,"title":["First-Trimester mRNA COVID-19 Vaccination and Risk of Major Congenital Anomalies"],"prefix":"10.1001","volume":"8","author":[{"given":"Cl\u00e9ment","family":"Bernard","sequence":"first","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), Saint-Denis, France"},{"name":"Centre for Epidemiology and Population Health (CESP), Anti-Infective Evasion and Pharmacoepidemiology Team, Paris-Saclay University, INSERM U1018, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Duchemin","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), Saint-Denis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Marty","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), Saint-Denis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Drouin","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), Saint-Denis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Miranda","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), Saint-Denis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Semenzato","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), Saint-Denis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Botton","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), Saint-Denis, France"},{"name":"Universit\u00e9 Paris-Saclay, Facult\u00e9 de pharmacie, Orsay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Chouchana","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), Saint-Denis, France"},{"name":"Regional Center of Pharmacovigilance, Department of Perinatal, Pediatric and Adult Pharmacology, Groupe Hospitalier-Universitaire AP-HP, H\u00f4pital Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Dray-Spira","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), Saint-Denis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Weill","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), Saint-Denis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), Saint-Denis, France"},{"name":"Centre for Epidemiology and Population Health (CESP), Anti-Infective Evasion and Pharmacoepidemiology Team, Paris-Saclay University, INSERM U1018, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"zoi251054r1","doi-asserted-by":"publisher","first-page":"m3320","DOI":"10.1136\/bmj.m3320","article-title":"Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis.","volume":"370","author":"Allotey","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"zoi251054r2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/1471-0528.16969","article-title":"Pregnancy and risk of COVID-19: a Norwegian registry-linkage study.","volume":"129","author":"Magnus","year":"2022","journal-title":"BJOG"},{"issue":"7","key":"zoi251054r3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/1471-0528.17135","article-title":"Impact of SARS-CoV-2 infection on risk of prematurity, birthweight and obstetric complications: a multivariate analysis from a nationwide, population-based retrospective cohort study.","volume":"129","author":"Simon","year":"2022","journal-title":"BJOG"},{"issue":"11","key":"zoi251054r4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003857","article-title":"Obstetrical outcomes and maternal morbidities associated with COVID-19 in pregnant women in France: a national retrospective cohort study.","volume":"18","author":"Epelboin","year":"2021","journal-title":"PLoS Med"},{"issue":"4","key":"zoi251054r5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/aogs.14329","article-title":"Management and implications of severe COVID-19 in pregnancy in the UK: data from the UK Obstetric Surveillance System national cohort.","volume":"101","author":"Vousden","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"8","key":"zoi251054r6","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1001\/jama.2022.1190","article-title":"Association of SARS-CoV-2 infection with serious maternal morbidity and mortality from obstetric complications.","volume":"327","author":"Metz","year":"2022","journal-title":"JAMA"},{"key":"zoi251054r7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069739","article-title":"Diagnosis and management of covid-19 in pregnancy.","volume":"377","author":"Nana","year":"2022","journal-title":"BMJ"},{"issue":"1","key":"zoi251054r8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s13054-023-04584-6","article-title":"Impact of Covid-19 on risk of severe maternal morbidity.","volume":"27","author":"Auger","year":"2023","journal-title":"Crit Care"},{"issue":"2","key":"zoi251054r9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-007730","article-title":"Global disparities in public health guidance for the use of COVID-19 vaccines in pregnancy.","volume":"7","author":"Zavala","year":"2022","journal-title":"BMJ Glob Health"},{"key":"zoi251054r11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069741","article-title":"Covid-19 vaccination in pregnancy.","volume":"378","author":"Badell","year":"2022","journal-title":"BMJ"},{"issue":"1","key":"zoi251054r12","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1038\/s41467-022-30052-w","article-title":"Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy.","volume":"13","author":"Prasad","year":"2022","journal-title":"Nat Commun"},{"issue":"10","key":"zoi251054r13","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41591-021-01490-8","article-title":"Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy.","volume":"27","author":"Dagan","year":"2021","journal-title":"Nat Med"},{"issue":"8","key":"zoi251054r14","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jama.2021.11035","article-title":"Association between BNT162b2 vaccination and incidence of SARS-CoV-2 infection in pregnant women.","volume":"326","author":"Goldshtein","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"zoi251054r15","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s41591-023-02270-2","article-title":"Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization.","volume":"29","author":"Lipschuetz","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"zoi251054r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52387","article-title":"Timing of maternal COVID-19 vaccine and antibody concentrations in infants born preterm.","volume":"7","author":"Kachikis","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi251054r17","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1038\/s41467-024-46694-x","article-title":"Maternal hybrid immunity and risk of infant COVID-19 hospitalizations: national case-control study in Israel.","volume":"15","author":"Guedalia","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"zoi251054r18","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/s41467-023-36547-4","article-title":"Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life.","volume":"14","author":"Zerbo","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"zoi251054r19","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.1038\/s41467-023-40965-9","article-title":"Neonatal and maternal outcomes following SARS-CoV-2 infection and COVID-19 vaccination: a population-based matched cohort study.","volume":"14","author":"Lindsay","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"zoi251054r20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2023-000632","article-title":"Pregnancy, fetal, and neonatal outcomes after a first booster dose of covid-19 vaccine during pregnancy in Ontario, Canada: population based, retrospective cohort study.","volume":"2","author":"Fell","year":"2023","journal-title":"BMJ Med"},{"issue":"5","key":"zoi251054r21","doi-asserted-by":"publisher","first-page":"585.e1","DOI":"10.1016\/j.ajog.2022.10.040","article-title":"Reductions in stillbirths and preterm birth in COVID-19-vaccinated women: a multicenter cohort study of vaccination uptake and perinatal outcomes.","volume":"228","author":"Hui","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"zoi251054r22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ijid.2023.01.018","article-title":"The dose- and time-dependent effectiveness and safety associated with COVID-19 vaccination during pregnancy: a systematic review and meta-analysis.","volume":"128","author":"Wu","year":"2023","journal-title":"Int J Infect Dis"},{"key":"zoi251054r23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071416","article-title":"Risk of preterm birth, small for gestational age at birth, and stillbirth after covid-19 vaccination during pregnancy: population based retrospective cohort study.","volume":"378","author":"Fell","year":"2022","journal-title":"BMJ"},{"issue":"1","key":"zoi251054r24","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.1038\/s41467-022-33937-y","article-title":"A population-based matched cohort study of early pregnancy outcomes following COVID-19 vaccination and SARS-CoV-2 infection.","volume":"13","author":"Calvert","year":"2022","journal-title":"Nat Commun"},{"issue":"5","key":"zoi251054r25","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/humrep\/dead036","article-title":"The risk of miscarriage following COVID-19 vaccination: a systematic review and meta-analysis.","volume":"38","author":"Rimmer","year":"2023","journal-title":"Hum Reprod"},{"key":"zoi251054r26","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1002\/bdra.20776","article-title":"Paper 2: EUROCAT public health indicators for congenital anomalies in Europe.","volume":"91","author":"Khoshnood","year":"2011","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"S1","key":"zoi251054r28","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1002\/bdra.20780","article-title":"Paper 1: the EUROCAT network\u2014organization and processes.","volume":"91","author":"Boyd","year":"2011","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"zoi251054r29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-079364","article-title":"Covid-19 infection and vaccination during first trimester and risk of congenital anomalies: Nordic registry based study.","volume":"386","author":"Magnus","year":"2024","journal-title":"BMJ"},{"issue":"1","key":"zoi251054r30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2023-000743","article-title":"Association between maternal mRNA covid-19 vaccination in early pregnancy and major congenital anomalies in offspring: population based cohort study with sibling matched analysis.","volume":"3","author":"Jorgensen","year":"2024","journal-title":"BMJ Med"},{"key":"zoi251054r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127070","article-title":"COVID-19 vaccination rates among pregnant women in France: a nationwide cohort study.","volume":"53","author":"Bernard","year":"2025","journal-title":"Vaccine"},{"key":"zoi251054r32","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-03119-x","article-title":"mRNA COVID vaccines saved lives and won a Nobel\u2014what\u2019s next for the technology?","author":"Dolgin","year":"2023","journal-title":"Nature"},{"issue":"11","key":"zoi251054r33","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","article-title":"mRNA vaccines for infectious diseases: advances, challenges and opportunities.","volume":"23","author":"Pardi","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"zoi251054r34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jama.2017.21269","article-title":"Association of hysteroscopic vs laparoscopic sterilization with procedural, gynecological, and medical outcomes.","volume":"319","author":"Bouillon","year":"2018","journal-title":"JAMA"},{"issue":"15","key":"zoi251054r35","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1056\/NEJMc2302134","article-title":"Stroke, myocardial infarction, and pulmonary embolism after bivalent booster.","volume":"388","author":"Jabagi","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"zoi251054r36","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1001\/jama.2024.16380","article-title":"Long-term prognosis of patients with myocarditis attributed to COVID-19 mRNA vaccination, SARS-CoV-2 infection, or conventional etiologies.","volume":"332","author":"Semenzato","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"zoi251054r37","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1038\/s41467-022-31401-5","article-title":"Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines.","volume":"13","author":"Le Vu","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"zoi251054r38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2021-000104","article-title":"Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study.","volume":"1","author":"Bouillon","year":"2022","journal-title":"BMJ Med"},{"issue":"1","key":"zoi251054r39","doi-asserted-by":"publisher","first-page":"7745","DOI":"10.1038\/s41467-024-52038-6","article-title":"Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis.","volume":"15","author":"Le Vu","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"zoi251054r40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004576","article-title":"First-trimester exposure to macrolides and risk of major congenital malformations compared with amoxicillin: a French nationwide cohort study.","volume":"22","author":"Tran","year":"2025","journal-title":"PLoS Med"},{"key":"zoi251054r41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.01.008","article-title":"Risks of 75 major congenital malformations after in utero exposure to thiopurines and anti-TNF for maternal inflammatory bowel disease.","author":"Meyer","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"zoi251054r44","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1093\/jac\/dkad266","article-title":"Prevalence and associated factors of antibiotic exposure during pregnancy in a large French population-based study during the 2010-19 period.","volume":"78","author":"Tran","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"zoi251054r45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245854","article-title":"Drug use for gastrointestinal symptoms during pregnancy: a French nationwide study 2010-2018.","volume":"16","author":"Meyer","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"zoi251054r46","doi-asserted-by":"publisher","DOI":"10.1002\/bdr2.2314","article-title":"Updated EUROCAT guidelines for classification of cases with congenital anomalies.","volume":"116","author":"Bergman","year":"2024","journal-title":"Birth Defects Res"},{"issue":"3","key":"zoi251054r47","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/aje\/kwj047","article-title":"Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect.","volume":"163","author":"Kurth","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"8","key":"zoi251054r48","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1093\/aje\/kwab041","article-title":"Propensity score weighting and trimming strategies for reducing variance and bias of treatment effect estimates: a simulation study.","volume":"190","author":"St\u00fcrmer","year":"2021","journal-title":"Am J Epidemiol"},{"key":"zoi251054r49","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100158","article-title":"Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people.","volume":"8","author":"Semenzato","year":"2021","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"zoi251054r50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2458-9-33","article-title":"Ecological association between a deprivation index and mortality in France over the period 1997-2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death.","volume":"9","author":"Rey","year":"2009","journal-title":"BMC Public Health"},{"key":"zoi251054r51","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102729","article-title":"In need of robust evidence of non-association of pregestational and early pregnancy SARS-CoV-2 infections with congenital anomalies.","volume":"74","author":"Samara","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"4","key":"zoi251054r52","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-069778","article-title":"COVID-19 vaccination during pregnancy and major structural birth defects.","volume":"155","author":"Rowe","year":"2025","journal-title":"Pediatrics"},{"issue":"6","key":"zoi251054r53","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/ppe.12650","article-title":"Quantification of selection bias in studies of risk factors for birth defects among livebirths.","volume":"34","author":"Heinke","year":"2020","journal-title":"Paediatr Perinat Epidemiol"},{"key":"zoi251054r42","author":"Miranda","year":"2023"},{"key":"zoi251054r43","author":"Marty","year":"2024"},{"key":"zoi251054r10","unstructured":"COMIT. Covid-19 maternal immunization tracker. Accessed April 29, 2025. https:\/\/www.comitglobal.org\/"},{"key":"zoi251054r27","unstructured":"European Commission. European platform on rare disease registration (EU RD Platform). Accessed June 5, 2022. https:\/\/eu-rd-platform.jrc.ec.europa.eu"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2840133\/bernard_2025_oi_251054_1759861242.58429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:01:56Z","timestamp":1760540516000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2840133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.38039","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}